Skip to content

Author

M. N. Nafash

We have 3 of 19 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Plasma biomarkers and incident clinical stage progression in the specialized memory clinic: a longitudinal study

INTRODUCTION: The utility of blood-based Alzheimer's disease (AD) biomarkers in predicting clinical trajectories remains uncertain. METHODS: We assessed the diagnostic and prognostic performance of p-tau181, p-tau217, GFAP, and NfL in a large memory-clinic cohort (n=3,645) with comprehensive baseline clinical evaluatio...

Xue-Mei Zeng, Nicholas Heaton, Rebecca A. Deek et al. · 0 citations
Open access Oct 2026

Plasma eMTBR-tau as a robust biomarker for Alzheimer's disease tangle pathology up to 10 years before death

Scalable and accessible biomarkers of neurofibrillary tangle pathology are needed for Alzheimer's disease prognosis, diagnosis and monitoring. Here, we show that a blood-based immunoassay for an endogenously-cleaved eMTBR-tau fragment of tau protein is strongly associated with autopsy-diagnosed Alzheimer neuropathologi...

R. Shi, X. Zeng, M. Farinas et al. · 0 citations
Open access Aug 2026

Association of age with clinical progression across plasma p-tau217 levels

These findings support further evaluation of age-contextualized plasma p-tau217 interpretation for prognosis and trial enrichment and support further evaluation of age-contextualized plasma p-tau217 interpretation for prognosis and trial enrichment.

R. Shi, L. Choity, S. Brodman et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.